according to this article Neuren did do animal testing for aged memory loss. Given the great results (according to this article) I am curious why this wouldn't have been pursued further by Neuren given the scale of the potential market?
https://www.biospace.com/article/releases/neuren-pharmaceuticals-limited-s-third-lead-drug-candidate-nnz-2591-proves-effective-at-reversing-memory-loss-/
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-29
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |